Testing & Diagnostics Session

Welcome and introduction
Saad Usmani & Sham Mailankody          

Part 1: Diagnostic approaches & new technologies
Chairs: Nizar Bahlis & Eric Smith

• Immunohistochemistry: Özgür Can Eren
• Illuminating GPRC5D expression through flow cytometry: From signal to insight: Diana Cortes-Selva
• NGS technologies to meet today’s requirements and challenges: Daniel Auclair
• Microbiome assessments: Kevin Miller
• The advantages and limitations of clinical sequencing tests in multiple myeloma: Jonathan Keats
• In situ hybridization and immunohistochemistry detection of GPRC5D expression in Von Ebner’s glands of human tongue: Roberto Guzman

Panel discussion 

Break

Part 2: Industry perspective on GPRC5D therapeutic approaches
Chairs: Saad Usmani & Sham Mailankody

• CAR T-cell therapy: TBC
• Evaluation of ramantamig in multiple myeloma models: Bradley Heidrich
• ADCs: TBC

Panel discussion

Part 3: Stakeholder panel discussion: Standardization & harmonization of GPRC5D assays
Chairs: Saad Usmani & Ahmet Dogan
Discussants: Eric Smith, Jonathan Keats, Bradley Heidrich, TBC, TBC

Testing & Diagnostics Session conclusions
Saad Usmani & & Sham Mailankody

Faculty dinner

General Session

Welcome and introduction
Saad Usmani, Sham Mailankody & Eric Smith

Session 1: Basic & translational
Chairs: Eric Smith & Ross Firestone

• Microbiome modulation and multiple myeloma progression in mouse models: Annamaria Ballweg
• What have we learnt about resistance to GPRC5D therapies?: Nizar Bahlis
• How do emerging translational studies influence sequencing?: Murali Janakiram

Panel discussion

Session 2: Clinical updates
Chairs: Doris Hansen & Carlyn Rose Tan

• JNJ-87562761, a GPRC5D enhanced effector function antibody for MM: Bradley Heidrich
• GPRC5D directed CAR T-cells: Jesús Berdeja
• GPRC5D antibody drug conjugates: Omar Nadeem
• GPRC5D T-cell engagers: Andrew Yee
• GPRC5D trispecific T-cell engagers: Saad Usmani
• Multi-antigen targeting: Yael Cohen

Panel discussion

Break

 

Session 3: Practical aspects of GPRC5D therapies
Chairs: Charlotte Pawlyn & Manisha Bhutani

• Real-world outcomes with talquetamab: Carlyn Rose Tan
• Older adults and GPRC5D therapies: Hira Mian
• Infectious complications: Tomáš Jelínek
• Neurologic toxicities with GPRC5D therapies: Doris Hansen
• GPRC5D-related ataxia: Murali Janakiram
• GI, skin, and oral toxicities: Joshua Richter

Panel discussion

 

Lunch

Session 4: Emerging use of GPRC5D-targeted therapies
Chairs: Roberto Mina & Hira Mian

• Talquetamab as bridging for BCMA CAR T cells: Binod Dhakal
• GPRC5D therapies for AL amyloidosis: Rajshekhar Chakraborty
• Is there a role for GPRC5D therapies in NDMM or early relapse?: Manisha Bhutani
• Outpatient administration and remote monitoring: Sridevi Rajeeve

Session 5: Translational approaches in GPRC5D-targeted therapies
Chairs: Francesco Maura & Annamaria Ballweg

• Predictors of response and resistance to talquetamab: Tarek Mouhieddine
• Primary resistance to GPRC5D therapies: Francesco Maura
• Immune profiling in GPRC5D therapies: Ross Firestone

Panel discussion

Session 6: Regulatory considerations for trial design and endpoints in GPRC5D-targeted therapies
Chairs: Saad Usmani & Sham Mailankody

• Regulatory landscape: surrogate endpoints: Charlotte Pawlyn
• Single or dual antigen targeting?: Hamza Hashmi

Panel discussion

Meeting conclusions & close
Saad Usmani, Sham Mailankody & Eric Smith